Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins

Rauch, Ursula; Osende, Julio I.; Chesebro, J H; Fuster, Valentín; Vorchheimer, David A.; Harris, Katie; Harris, Peter L.; Sandler, D.A.; Fallon, John T.; Jayaraman, Sudha; Badimon, Juan J.

doi:10.1016/s0021-9150(00)00397-x

Cited by 131 publications

(83 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…14, 15 We have reported an increased BT in hyperlipidemic patients and normalization of the increased thrombogenicity after the normalization of plasma cholesterol levels by statin administration. 23 More recently, it has been reported that lipid lowering by statin therapy has reduced TF expression and macrophage recruitment in atherosclerotic rabbits and reduced cholesterol-induced thrombogenicity. 29,30 In conclusion, our data indicate the following: (1) Increased BT in poorly controlled T2DM seems to be related to plasma levels of a circulating pool of activatable TF activity; (2) improvements in glycemic control are associated with a reduction in plasma levels of circulating TF activity and BT; and (3) risk factors such as hyperlipidemia and smoking have a significant modulatory effect on plasma levels of circulating TF and BT.…”

Section: Discussionmentioning

confidence: 99%

Role of Risk Factors in the Modulation of Tissue Factor Activity and Blood Thrombogenicity

et al. 2003

View full text Add to dashboard Cite

Background-Several studies suggest a role for an increased circulating pool of tissue factor (TF) in atherothrombotic diseases. Furthermore, certain cardiovascular risk factors, such as diabetes, hyperlipemia, and smoking, are associated with a higher incidence of thrombotic complications. We hypothesized that the observed increased blood thrombogenicity (BT) observed in patients with type 2 diabetes mellitus may be mediated via an increased circulating tissue factor activity. We have extended our study to smokers and hyperlipidemic subjects. Methods and Results-Poorly controlled patients with type 2 diabetes mellitus (nϭ36), smokers (nϭ10), and untreated hyperlipidemic subjects (nϭ10) were studied. Circulating TF was immunocaptured from plasma, relipidated, and quantified by factor Xa (FXa) generation in the presence of factor VIIa. BT was assessed as thrombus formation on the Badimon perfusion chamber.

show abstract

Section: Discussionmentioning

confidence: 99%

Role of Risk Factors in the Modulation of Tissue Factor Activity and Blood Thrombogenicity

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Statins have been further shown to decrease thrombus formation, in parallel with treatment-induced reduction in LDL cholesterol levels, in hypercholesterolemic patients 70) . Clinical studies have demonstrated that statins, as a class, promote reproducible reductions in CRP levels related to their potency.…”

Section: Lipid Lowering and Reduced Inflammation With Statinsmentioning

confidence: 99%

Inflammation and the Development of Atherosclerosis

Mizuno

Jacob²,

Mason

2011

JAT

147

113

View full text Add to dashboard Cite

“…Statin administration significantly reduces the risk of cardiovascular disease in susceptible patients, largely by lowering plasma lipid concentration. In addition, statins have been found to exert anti-inflammatory and immunomodulatory actions (Blanco-Colio et al, 2003), as well as alleviating endothelial dysfunction (O'Driscoll et al, 1997), and reducing thrombotic tendencies in the blood (Rauch et al, 2000).…”

Section: Introductionmentioning

confidence: 99%

Simvastatin Decreases IL-6 and IL-8 Production in Epithelial Cells

et al. 2006

View full text Add to dashboard Cite

Many cardiovascular studies have suggested that 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitors (statins) have anti-inflammatory effects independent of cholesterol lowering. As a chronic inflammatory disease, periodontitis shares some mechanisms with atherosclerosis. Since oral epithelial cells participate importantly in periodontal inflammation, we measured simvastatin effects on interleukin-6 and interleukin-8 production by cultured human epithelial cell line (KB cells) in response to interleukin-1α. Simvastatin decreased production, an effect reversed by adding mevalonate or geranylgeranyl pyrophosphate, but not farnesyl pyrophosphate. Simvastatin was found to reduce NF-κB and AP-1 promoter activity in KB cells. Dominantnegative Rac1 severely inhibited interleukin-1α-induced NF-κB and AP-1 promoter activity. Our results may indicate an anti-inflammatory effect of simvastatin on human oral epithelial cells, apparently involving Rac1 GTPase inhibition.

show abstract

Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins

Cited by 131 publications

References 34 publications

Role of Risk Factors in the Modulation of Tissue Factor Activity and Blood Thrombogenicity

Role of Risk Factors in the Modulation of Tissue Factor Activity and Blood Thrombogenicity

Inflammation and the Development of Atherosclerosis

Simvastatin Decreases IL-6 and IL-8 Production in Epithelial Cells

Contact Info

Product

Resources

About